AbbVie Inc (ABBV)vsMirum Pharmaceuticals Inc (MIRM)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
MIRM
Mirum Pharmaceuticals Inc
$107.16
+4.11%
HEALTHCARE · Cap: $6.28B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11950% more annual revenue ($62.82B vs $521.31M). ABBV leads profitability with a 5.8% profit margin vs -4.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MIRM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Margin of Safety
+47.2%
Fair Value
$189.03
Current Price
$107.16
$81.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Revenue surging 49.8% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Trading at 17.7x book value
0.0% earnings growth
ROE of -8.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 49.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : MIRM
The primary concerns for MIRM are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while MIRM is a hypergrowth play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.52 — expect wider price swings.
MIRM is growing revenue faster at 49.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. MIRM offers better value entry with a 47.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?